Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study

(2020) Yakeel T Quiroz et al.   LANCET NEUROLOGY

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment

(2020) Philip S. Insel et al.   JAMA Neurology

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

(2020) Jasmeer P. Chhatwal et al.   Nature Communications

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Determining clinically meaningful decline in preclinical Alzheimer disease

(2019) Philip S. Insel et al.   NEUROLOGY

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

(2019) Ingrid S van Maurik et al.   LANCET NEUROLOGY

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project

(2017) Ingrid S. van Maurik et al.   JAMA Neurology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration

(2016) Henrik Zetterberg   NEURON

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis

(2016) Niklas Mattsson et al.   Nature Communications

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

(2016) Julio C. Rojas et al.   Annals of Clinical and Translational Neurology

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET

(2016) Danielle van Westen et al.   Scientific Reports

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

(2009) John C. Morris et al.   ANNALS OF NEUROLOGY